Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03037645 · ClinicalTrials.gov registry record · Phase 1
Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers
A Phase 1 study, sponsored by Sunesis Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 39
- Enrollment target
NCT03037645 is a Phase 1 study that was terminated before completion, run by Sunesis Pharmaceuticals. The registered enrollment target is 39 participants.
The verdict
NCT03037645, a Phase 1 study, was terminated before completion, sponsored by Sunesis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 39 participants
- Enrollment target
Study Summary
This is an open-label Phase 1b/2 study in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)or non hodgkin's lymphoma (NHL) who have failed prior standard of care therapies including a BTK inhibitor where one is approved for the indication.
Interventions
- DRUG SNS-062
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2017-04-28 |
| Est. Completion | 2020-08-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03037645
The ClinicalTrials.gov registry entry for NCT03037645 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sunesis Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SNS-062 is the first listed.
NCT03037645 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03037645 about?
NCT03037645 is a clinical study titled "Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers". This is an open-label Phase 1b/2 study in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)or non hodgkin's lymphoma (NHL) who have failed prior standard of care therapies including a BTK inhibitor where one is approved for the indication.
What is the current status of trial NCT03037645?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2017-04-28. Estimated completion is 2020-08-31.
What interventions are being tested in trial NCT03037645?
The interventions under investigation include: SNS-062 (DRUG).
Who is sponsoring clinical trial NCT03037645?
This trial is sponsored by Sunesis Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.